Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Multiple Sclerosis

Free Subscription Articles published in Ann Neurol Retrieve available abstracts of 87 articles: HTML format

Single Articles

November 2024
1. BROWNLEE WJ, Vidal-Jordana A, Shatila M, Strijbis E, et al
   Towards a Unified Set of Diagnostic Criteria for Multiple Sclerosis.
   Ann Neurol. 2024 Nov 28. doi: 10.1002/ana.27145.
   PubMed     Abstract available
   
   
   
2. PROTOPAPA M, Steffen F, Schraad M, Ruck T, et al
   Increased Disability Progression in rs10191329(AA) Carriers with Multiple Sclerosis Is Preceded by Neurofilament Light Chain Elevations.
   Ann Neurol. 2024 Nov 26. doi: 10.1002/ana.27144.
   PubMed     Abstract available
   
   
   
3. MEUTH SG, Wolff S, Muck A, Willison A, et al
   Different Treatment Outcomes of Multiple Sclerosis Patients Receiving Ocrelizumab or Ofatumumab.
   Ann Neurol. 2024 Nov 25. doi: 10.1002/ana.27143.
   PubMed     Abstract available
   
   
   October 2024
4. ALZAMANAN F, Ding Y, Harroud A
   Obesity and Multiple Sclerosis Severity: A Mendelian Randomization Study.
   Ann Neurol. 2024 Oct 21. doi: 10.1002/ana.27112.
   PubMed     Abstract available
   
   
   
5. MESSMER ML, Salapa HE, Popescu BF, Levin MC, et al
   RNA Binding Protein Dysfunction Links Smoldering/Slowly Expanding Lesions to Neurodegeneration in Multiple Sclerosis.
   Ann Neurol. 2024 Oct 18. doi: 10.1002/ana.27114.
   PubMed     Abstract available
   
   
   
6. BENKERT P, Maleska Maceski A, Schaedelin S, Oechtering J, et al
   Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels Reflect Different Mechanisms of Disease Progression under B-Cell Depleting Treatment in Multiple Sclerosis.
   Ann Neurol. 2024 Oct 16. doi: 10.1002/ana.27096.
   PubMed     Abstract available
   
   
   
7. SANABRIA-DIAZ G, Cagol A, Lu PJ, Barakovic M, et al
   Advanced MRI Measures of Myelin and Axon Volume Identify Repair in Multiple Sclerosis.
   Ann Neurol. 2024 Oct 10. doi: 10.1002/ana.27102.
   PubMed     Abstract available
   
   
   
8. MONTOBBIO N, Cordioli C, Signori A, Bovis F, et al
   Relapse-Associated and Relapse-Independent Contribution to Overall Expanded Disability Status Scale Progression in Multiple Sclerosis Patients Diagnosed in Different Eras.
   Ann Neurol. 2024 Oct 9. doi: 10.1002/ana.27093.
   PubMed     Abstract available
   
   
   September 2024
9. FADDA G, Banwell B, Elliott C, Fetco D, et al
   Slowly Expanding Lesions Differentiate Pediatric Multiple Sclerosis from Myelin Oligodendrocyte Glycoprotein Antibody Disease.
   Ann Neurol. 2024 Sep 7. doi: 10.1002/ana.27066.
   PubMed     Abstract available
   
   
   August 2024
10. GRUT V, Bistrom M, Salzer J, Stridh P, et al
    Interactions between High Seroreactivity to Human Herpes Virus 6A and Epstein-Barr Virus in MS Development: A Presymptomatic Case-Control Study.
    Ann Neurol. 2024;96:302-305.
    PubMed     Abstract available
    
    
    July 2024
11. MARRODAN M, Calandri IL, Bocancea DI, Ysrraelit MC, et al
    Diagnostic MRI Score to Differentiate Susac Syndrome from Primary Angiitis of the Central Nervous System and Multiple Sclerosis.
    Ann Neurol. 2024 Jul 26. doi: 10.1002/ana.27043.
    PubMed     Abstract available
    
    
    
12. SCALFARI A, Traboulsee A, Oh J, Airas L, et al
    Smouldering-Associated Worsening in Multiple Sclerosis: An International Consensus Statement on Definition, Biology, Clinical Implications, and Future Directions.
    Ann Neurol. 2024 Jul 25. doi: 10.1002/ana.27034.
    PubMed     Abstract available
    
    
    
13. HU Y, Frisell T, Alping P, Song H, et al
    Hospital-Treated Infections and Risk of Disability Worsening in Multiple Sclerosis.
    Ann Neurol. 2024 Jul 10. doi: 10.1002/ana.27026.
    PubMed     Abstract available
    
    
    
14. BRIER MR, Schindler SE, Salter A, Perantie D, et al
    Unexpected Low Rate of Amyloid-beta Pathology in Multiple Sclerosis Patients.
    Ann Neurol. 2024 Jul 4. doi: 10.1002/ana.27027.
    PubMed     Abstract available
    
    
    June 2024
15. PIEHL F, Alping P, Virtanen S, Englund S, et al
    COMBAT-MS: A Population-Based Observational Cohort Study Addressing the Benefit-Risk Balance of Multiple Sclerosis Therapies Compared with Rituximab.
    Ann Neurol. 2024 Jun 25. doi: 10.1002/ana.27012.
    PubMed     Abstract available
    
    
    May 2024
16. CORTESE R, Battaglini M, Prados F, Gentile G, et al
    Grey Matter Atrophy and its Relationship with White Matter Lesions in Patients with Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder, and Multiple Sclerosis.
    Ann Neurol. 2024 May 23. doi: 10.1002/ana.26951.
    PubMed     Abstract available
    
    
    
17. GIORDANO A, Pignolet B, Mascia E, Clarelli F, et al
    DNA Methylation in the Anti-Mullerian Hormone Gene and the Risk of Disease Activity in Multiple Sclerosis.
    Ann Neurol. 2024 May 15. doi: 10.1002/ana.26959.
    PubMed     Abstract available
    
    
    April 2024
18. CALABRESE M, Preziosa P, Scalfari A, Colato E, et al
    Determinants and Biomarkers of Progression Independent of Relapses in Multiple Sclerosis.
    Ann Neurol. 2024 Apr 3. doi: 10.1002/ana.26913.
    PubMed     Abstract available
    
    
    March 2024
19. NEIDHART S, Vlad B, Hilty M, Hogelin KA, et al
    HLA Associations of Intrathecal IgG Production against Specific Viruses in Multiple Sclerosis.
    Ann Neurol. 2024 Mar 29. doi: 10.1002/ana.26921.
    PubMed     Abstract available
    
    
    
20. ALPING P, Neovius M, Piehl F, Frisell T, et al
    Real-World Healthcare Cost Savings and Reduced Relapse Rate with Off-Label Rituximab versus Disease-Modifying Treatments Approved for Relapsing-Remitting Multiple Sclerosis: A Nationwide Cost-Effectiveness Study.
    Ann Neurol. 2024 Mar 26. doi: 10.1002/ana.26914.
    PubMed     Abstract available
    
    
    
21. MARGONI M, Pagani E, Meani A, Preziosa P, et al
    Cognitive Impairment Is Related to Glymphatic System Dysfunction in Pediatric Multiple Sclerosis.
    Ann Neurol. 2024 Mar 13. doi: 10.1002/ana.26911.
    PubMed     Abstract available
    
    
    February 2024
22. FADDA G, Yea C, O'Mahony J, Waters P, et al
    Epstein-Barr Virus Strongly Associates With Pediatric Multiple Sclerosis, But Not Myelin Oligodendrocyte Glycoprotein-Antibody-Associated Disease.
    Ann Neurol. 2024 Feb 27. doi: 10.1002/ana.26890.
    PubMed     Abstract available
    
    
    
23. CHOMYK A, Kucinski R, Kim J, Christie E, et al
    Transcript Profiles of Microglia/Macrophage Cells at the Borders of Chronic Active and Subpial Gray Matter Lesions in Multiple Sclerosis.
    Ann Neurol. 2024 Feb 12. doi: 10.1002/ana.26877.
    PubMed     Abstract available
    
    
    December 2023
24. NICHOLAS R, Magliozzi R, Marastoni D, Howell O, et al
    High levels of perivascular inflammation and active demyelinating lesions at time of death associated with rapidly progressive multiple sclerosis disease course: a retrospective post-mortem cohort study.
    Ann Neurol. 2023 Dec 27. doi: 10.1002/ana.26870.
    PubMed     Abstract available
    
    
    
25. MCKAY KA, Wijnands JMA, Manouchehrinia A, Zhu F, et al
    Risk of Multiple Sclerosis in People Living with HIV: An International Cohort Study.
    Ann Neurol. 2023 Dec 14. doi: 10.1002/ana.26840.
    PubMed     Abstract available
    
    
    
26. KIM S, Eun MY, Lee JJ, Seok HY, et al
    Myelin Oligodendrocyte Glycoprotein Antibody-Positive Patients Meeting the 2017 McDonald Criteria for Multiple Sclerosis: Challenges in Diagnosis and Treatment Decisions.
    Ann Neurol. 2023 Dec 12. doi: 10.1002/ana.26859.
    PubMed    
    
    
    
27. VILLACIEROS-ALVAREZ J, Espejo C, Cobo-Calvo A
    Reply to "Myelin Oligodendrocyte Glycoprotein Antibody-Positive Patients Meeting the 2017 McDonald Criteria for Multiple Sclerosis: Challenges in Diagnosis and Treatment Decisions".
    Ann Neurol. 2023 Dec 11. doi: 10.1002/ana.26856.
    PubMed    
    
    
    
28. KNOWLES S, Middleton R, Cooze B, Farkas I, et al
    Comparing the pathology, clinical and demographic characteristics of younger and older-onset multiple sclerosis.
    Ann Neurol. 2023 Dec 7. doi: 10.1002/ana.26843.
    PubMed     Abstract available
    
    
    November 2023
29. KREFT KL, Uzochukwu E, Loveless S, Willis M, et al
    Relevance of multiple sclerosis severity genotype in predicting disease course: A real-world cohort.
    Ann Neurol. 2023 Nov 17. doi: 10.1002/ana.26831.
    PubMed     Abstract available
    
    
    September 2023
30. GASPERI C, Wiltgen T, McGinnis J, Cerri S, et al
    A genetic risk variant for multiple sclerosis severity is associated with brain atrophy.
    Ann Neurol. 2023 Sep 27. doi: 10.1002/ana.26807.
    PubMed     Abstract available
    
    
    
31. VILLACIEROS-ALVAREZ J, Espejo C, Arrambide G, Castillo M, et al
    MOG antibodies in adults with a first demyelinating event suggestive of multiple sclerosis.
    Ann Neurol. 2023 Sep 14. doi: 10.1002/ana.26793.
    PubMed     Abstract available
    
    
    August 2023
32. ADINGUPU DD, Evans T, Soroush A, Hansen A, et al
    Temporal pattern of cortical hypoxia in Multiple Sclerosis and its significance on neuropsychological and clinical measures of disability.
    Ann Neurol. 2023 Aug 22. doi: 10.1002/ana.26769.
    PubMed     Abstract available
    
    
    July 2023
33. SORMANI MP, Schiavetti I, Ponzano M, Colato E, et al
    Treatment Effect on Brain Atrophy Correlates with Treatment Effect on Cognition in Multiple Sclerosis.
    Ann Neurol. 2023 Jul 26. doi: 10.1002/ana.26751.
    PubMed     Abstract available
    
    
    June 2023
34. CLARK KA, Manning AR, Chen L, Liu F, et al
    Early MRI features of new paramagnetic rim lesions in Multiple Sclerosis.
    Ann Neurol. 2023 Jun 21. doi: 10.1002/ana.26727.
    PubMed     Abstract available
    
    
    May 2023
35. HOLM HANSEN R, von Essen MR, Mahler MR, Cobanovic S, et al
    Cladribine effects on T and B cells and T cell reactivity in multiple sclerosis.
    Ann Neurol. 2023 May 16. doi: 10.1002/ana.26684.
    PubMed     Abstract available
    
    
    
36. PATRICK MT, Nair RP, He K, Stuart PE, et al
    Shared Genetic Risk Factors for Multiple Sclerosis/Psoriasis Suggest Involvement of Interleukin-17 and Janus Kinase-Signal Transducers and Activators of Transcription Signaling.
    Ann Neurol. 2023 May 1. doi: 10.1002/ana.26672.
    PubMed     Abstract available
    
    
    April 2023
37. HAMZAOUI M, Garcia J, Boffa G, Lazzarotto A, et al
    Positron emission tomography with [(18) F]-DPA-714 unveils a smoldering component in most multiple sclerosis lesions which drives disease progression.
    Ann Neurol. 2023 Apr 11. doi: 10.1002/ana.26657.
    PubMed     Abstract available
    
    
    March 2023
38. BAKIRTZIS C, Langdon DW, Grigoriadis N
    Time to rebaseline cognitive performance in people with multiple sclerosis?
    Ann Neurol. 2023 Mar 8. doi: 10.1002/ana.26628.
    PubMed    
    
    
    February 2023
39. KALLURI HV, Rosebraugh MR, Misko TP, Ziemann A, et al
    Phase 1 Evaluation of Elezanumab (Anti-Repulsive Guidance Molecule A Monoclonal Antibody) in Healthy and Multiple Sclerosis Participants.
    Ann Neurol. 2023;93:285-296.
    PubMed     Abstract available
    
    
    December 2022
40. VAN DEN BOSCH AMR, Hummert S, Steyer A, Ruhwedel T, et al
    Ultrastructural Axon-Myelin Unit Alterations in Multiple Sclerosis Correlate with Inflammation.
    Ann Neurol. 2022 Dec 24. doi: 10.1002/ana.26585.
    PubMed     Abstract available
    
    
    November 2022
41. OKUDA DT, Kantarci O, Lebrun-Frenay C, Sormani MP, et al
    Dimethyl fumarate delays multiple sclerosis in radiologically isolated syndrome.
    Ann Neurol. 2022 Nov 18. doi: 10.1002/ana.26555.
    PubMed     Abstract available
    
    
    
42. GARCIA-MONTOJO M, Simula ER, Fathi S, McMahan C, et al
    Antibody Response to HML-2 May Be Protective in Amyotrophic Lateral Sclerosis.
    Ann Neurol. 2022;92:782-792.
    PubMed     Abstract available
    
    
    October 2022
43. VAN KEMPEN ZLE, Hogenboom L, Toorop AA, Steenhuis M, et al
    Ocrelizumab concentration is a good predictor of SARS-CoV-2 vaccination response in patients with multiple sclerosis.
    Ann Neurol. 2022 Oct 17. doi: 10.1002/ana.26534.
    PubMed     Abstract available
    
    
    
44. MURPHY OC, Sotirchos ES, Kalaitzidis G, Vasileiou E, et al
    Trans-synaptic degeneration following acute optic neuritis in multiple sclerosis.
    Ann Neurol. 2022 Oct 11. doi: 10.1002/ana.26529.
    PubMed     Abstract available
    
    
    September 2022
45. GAUDIOSO CM, Mar S, Casper TC, Codden R, et al
    MOG and AQP4 antibodies among children with multiple sclerosis and controls.
    Ann Neurol. 2022 Sep 11. doi: 10.1002/ana.26502.
    PubMed     Abstract available
    
    
    June 2022
46. MAGLIOZZI R, Fadda G, Brown RA, Bar-Or A, et al
    "Ependymal-in" gradient of thalamic damage in progressive multiple sclerosis.
    Ann Neurol. 2022 Jun 24. doi: 10.1002/ana.26448.
    PubMed     Abstract available
    
    
    
47. RAHMANZADEH R, Galbusera R, Lu PJ, Bahn E, et al
    A new advanced MRI biomarker for remyelinated lesions in Multiple Sclerosis.
    Ann Neurol. 2022 Jun 17. doi: 10.1002/ana.26441.
    PubMed     Abstract available
    
    
    
48. OECHTERING J, Lincke T, Schaedelin S, Decard BF, et al
    Intrathecal IgM Synthesis Is Associated with Spinal Cord Manifestation and Neuronal Injury in Early MS.
    Ann Neurol. 2022;91:814-820.
    PubMed     Abstract available
    
    
    May 2022
49. ZEYDAN B, Rocca MA, Kantarci OH, Filippi M, et al
    Spinal Cord Atrophy Is a Preclinical Marker of Progressive MS.
    Ann Neurol. 2022;91:734-735.
    PubMed    
    
    
    
50. GHIROTTO B, Oliveira DF, Cipelli M, Basso PJ, et al
    MS-Driven Metabolic Alterations Are Recapitulated in iPSC-Derived Astrocytes.
    Ann Neurol. 2022;91:652-669.
    PubMed     Abstract available
    
    
    
51. DIEBOLD M, Galli E, Kopf A, Sanderson N, et al
    Immunological Predictors of Dimethyl Fumarate-Induced Lymphopenia.
    Ann Neurol. 2022;91:676-681.
    PubMed     Abstract available
    
    
    April 2022
52. BOSE G, Healy BC, Lokhande HA, Sotiropoulos MG, et al
    Early predictors of clinical and MRI outcomes using LASSO in multiple sclerosis.
    Ann Neurol. 2022 Apr 15. doi: 10.1002/ana.26370.
    PubMed     Abstract available
    
    
    March 2022
53. KISTER I, Patskovsky Y, Curtin R, Pei J, et al
    Cellular and humoral immunity to SARS-CoV-2 infection in multiple sclerosis patients on ocrelizumab and other disease-modifying therapies: a multi-ethnic observational study.
    Ann Neurol. 2022 Mar 15. doi: 10.1002/ana.26346.
    PubMed     Abstract available
    
    
    
54. LANGER-GOULD A, Cheng SC, Li BH, Smith JB, et al
    Decreasing Multiple Sclerosis Treatment Expenditures and Improving Quality at the Health System Level.
    Ann Neurol. 2022 Mar 13. doi: 10.1002/ana.26352.
    PubMed     Abstract available
    
    
    
55. BRILL L, Raposo C, Rechtman A, Zveik O, et al
    SARS-CoV-2 third vaccine immune response in MS patients treated with ocrelizumab.
    Ann Neurol. 2022 Mar 4. doi: 10.1002/ana.26343.
    PubMed     Abstract available
    
    
    February 2022
56. DE MEO E, Filippi M, Trojano M, Comi G, et al
    Comparing natural history of early and late onset pediatric multiple sclerosis.
    Ann Neurol. 2022 Feb 12. doi: 10.1002/ana.26322.
    PubMed     Abstract available
    
    
    January 2022
57. MCKAY KA, Bedri SK, Manouchehrinia A, Stawiarz L, et al
    Reduction in cognitive processing speed surrounding multiple sclerosis relapse.
    Ann Neurol. 2022 Jan 4. doi: 10.1002/ana.26301.
    PubMed     Abstract available
    
    
    December 2021
58. FLEISCHER V, Ciolac D, Gonzalez-Escamilla G, Grothe M, et al
    Subcortical volumes as early predictors of fatigue in multiple sclerosis.
    Ann Neurol. 2021 Dec 30. doi: 10.1002/ana.26290.
    PubMed     Abstract available
    
    
    
59. BISCHOF A, Papinutto N, Keshavan A, Rajesh A, et al
    Spinal cord atrophy predicts progressive disease in relapsing multiple sclerosis.
    Ann Neurol. 2021 Dec 8. doi: 10.1002/ana.26281.
    PubMed     Abstract available
    
    
    November 2021
60. QUENDT C, Ochs J, Hausser-Kinzel S, Hausler D, et al
    Proinflammatory CD20(+) T Cells are Differentially Affected by Multiple Sclerosis Therapeutics.
    Ann Neurol. 2021;90:834-839.
    PubMed     Abstract available
    
    
    October 2021
61. TALLANTYRE EC, Vickaryous N, Anderson V, Asardag AN, et al
    COVID-19 vaccine response in people with multiple sclerosis.
    Ann Neurol. 2021 Oct 22. doi: 10.1002/ana.26251.
    PubMed     Abstract available
    
    
    September 2021
62. KOCH MW, Kaur S, Sage K, Kim J, et al
    Hydroxychloroquine for Primary Progressive Multiple Sclerosis.
    Ann Neurol. 2021 Sep 30. doi: 10.1002/ana.26239.
    PubMed     Abstract available
    
    
    August 2021
63. KIMURA K, Lin Y, Yamaguchi H, Sato W, et al
    Th1 - CD11c(+) B cell axis associated with response to plasmapheresis in multiple sclerosis.
    Ann Neurol. 2021 Aug 23. doi: 10.1002/ana.26202.
    PubMed     Abstract available
    
    
    
64. PAN S, Chan JR
    Clinical Applications of Myelin Plasticity for Remyelinating Therapies in Multiple Sclerosis.
    Ann Neurol. 2021 Aug 17. doi: 10.1002/ana.26196.
    PubMed     Abstract available
    
    
    
65. KOLB H, Absinta M, Beck ES, Ha SK, et al
    7T MRI Differetiates Remyelinated from Demyelinated Multiple Sclerosis Lesions.
    Ann Neurol. 2021 Aug 14. doi: 10.1002/ana.26194.
    PubMed     Abstract available
    
    
    July 2021
66. METZ I, Gavrilova RH, Weigand SD, Frischer JM, et al
    MRI Correlates of Multiple Sclerosis Immunopathological Patterns.
    Ann Neurol. 2021 Jul 7. doi: 10.1002/ana.26163.
    PubMed     Abstract available
    
    
    
67. GELIBTER S, Pisa M, Croese T, Finardi A, et al
    Spinal fluid myeloid microvesicles predict disease course in multiple sclerosis.
    Ann Neurol. 2021 Jul 3. doi: 10.1002/ana.26154.
    PubMed     Abstract available
    
    
    
68. HAUSER SL
    Curing Multiple Sclerosis: How to Know When We're There?
    Ann Neurol. 2021 Jul 2. doi: 10.1002/ana.26155.
    PubMed    
    
    
    May 2021
69. OECHTERING J, Schaedelin S, Benkert P, Muller S, et al
    Intrathecal Immunoglobulin M synthesis is an independent biomarker for higher disease activity and severity in multiple sclerosis.
    Ann Neurol. 2021 May 31. doi: 10.1002/ana.26137.
    PubMed     Abstract available
    
    
    
70. AKTAS O, Smith MA, Rees WA, Bennett JL, et al
    Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker.
    Ann Neurol. 2021;89:895-910.
    PubMed     Abstract available
    
    
    April 2021
71. COX LM, Maghzi AH, Liu S, Tankou SK, et al
    The Gut Microbiome in Progressive Multiple Sclerosis.
    Ann Neurol. 2021 Apr 19. doi: 10.1002/ana.26084.
    PubMed     Abstract available
    
    
    
72. PETZOLD A
    Reply to "Peripapillary Hyper-Reflective Ovoid Masslike Structures in Astronauts".
    Ann Neurol. 2021;89:849-850.
    PubMed    
    
    
    
73. WOSTYN P, Gibson CR, Mader TH
    Peripapillary Hyper-Reflective Ovoid Mass-Like Structures in Astronauts.
    Ann Neurol. 2021;89:849.
    PubMed    
    
    
    
74. LUCHICCHI A, Hart B, Frigerio I, van Dam AM, et al
    Axon-Myelin Unit Blistering as Early Event in MS Normal Appearing White Matter.
    Ann Neurol. 2021;89:711-725.
    PubMed     Abstract available
    
    
    March 2021
75. VANDEBERGH M, Andlauer TFM, Zhou Y, Mallants K, et al
    Genetic variation in WNT9B increases relapse hazard in multiple sclerosis.
    Ann Neurol. 2021 Mar 11. doi: 10.1002/ana.26061.
    PubMed     Abstract available
    
    
    
76. NOURBAKHSH B, Cordano C, Asteggiano C, Ruprecht K, et al
    Multiple Sclerosis Is Rare in Epstein-Barr Virus-Seronegative Children with Central Nervous System Inflammatory Demyelination.
    Ann Neurol. 2021 Mar 11. doi: 10.1002/ana.26062.
    PubMed     Abstract available
    
    
    February 2021
77. DE MEO E, Bonacchi R, Moiola L, Colombo B, et al
    Early predictors of 9-year disability in pediatric multiple sclerosis.
    Ann Neurol. 2021 Feb 17. doi: 10.1002/ana.26052.
    PubMed     Abstract available
    
    
    January 2021
78. SORMANI MP, De Rossi N, Schiavetti I, Carmisciano L, et al
    Disease modifying therapies and Covid-19 severity in Multiple Sclerosis.
    Ann Neurol. 2021 Jan 21. doi: 10.1002/ana.26028.
    PubMed     Abstract available
    
    
    November 2020
79. THAM M, Frischer JM, Weigand SD, Fitz-Gibbon PD, et al
    Iron heterogeneity in early active multiple sclerosis lesions.
    Ann Neurol. 2020 Nov 27. doi: 10.1002/ana.25974.
    PubMed     Abstract available
    
    
    
80. FADDA G, Banwell B, Waters P, Marrie RA, et al
    Silent new brain MRI lesions in children with MOG-antibody associated disease.
    Ann Neurol. 2020 Nov 19. doi: 10.1002/ana.25957.
    PubMed     Abstract available
    
    
    October 2020
81. SOTIRCHOS ES, Calabresi PA, Saidha S
    Reply to "Retinal INL thickness in multiple sclerosis: a mere marker of neurodegeneration?"
    Ann Neurol. 2020 Oct 17. doi: 10.1002/ana.25936.
    PubMed    
    
    
    
82. CORDANO C, Yiu HH, Oertel FC, Gelfand JM, et al
    Retinal INL thickness in multiple sclerosis: a mere marker of neurodegeneration?
    Ann Neurol. 2020 Oct 17. doi: 10.1002/ana.25933.
    PubMed    
    
    
    
83. COMI G, Bar-Or A, Lassmann H, Uccelli A, et al
    The role of B cells in Multiple Sclerosis and related disorders.
    Ann Neurol. 2020 Oct 9. doi: 10.1002/ana.25927.
    PubMed     Abstract available
    
    
    September 2020
84. CIOTTI JR, Grebenciucova E, Moss BP, Newsome SD, et al
    Multiple Sclerosis Disease-Modifying Therapies in the COVID-19 Era.
    Ann Neurol. 2020 Sep 19. doi: 10.1002/ana.25907.
    PubMed    
    
    
    August 2020
85. PETZOLD A, Coric D, Balk LJ, Hamann S, et al
    Longitudinal Development of Peripapillary Hyper-Reflective Ovoid Masslike Structures Suggests a Novel Pathological Pathway in Multiple Sclerosis.
    Ann Neurol. 2020;88:309-319.
    PubMed     Abstract available
    
    
    July 2020
86. KRYSKO KM, Graves JS, Rensel M, Weinstock-Guttman B, et al
    Real-World Effectiveness of Initial Disease-Modifying Therapies in Pediatric Multiple Sclerosis.
    Ann Neurol. 2020;88:42-55.
    PubMed     Abstract available
    
    
    June 2020
87. LEBRUN-FRENAY C, Kantarci O, Siva A, Sormani MP, et al
    Radiologically Isolated Syndrome: 10-Year Risk Estimate of a Clinical Event.
    Ann Neurol. 2020 Jun 4. doi: 10.1002/ana.25799.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Multiple Sclerosis is free of charge.